Shares of Travere Therapeutics Inc. (TVTX) were up over 8% at $10.25 in after-hours trading Thursday, following favorable regulatory news.
The FDA has granted full approval to Filspari to slow kidney function decline in adults with primary immunoglobulin A nephropathy (IgAN) at risk of rapid disease progression.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com